Australia

Recce Pharmaceuticals

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

Australia

Post An Enquiry

Virtual Booth

ESMO 2020 Congress

Participation Not Confirmed

Update your events

Recce Pharmaceuticals Receives Entrepreneurs’ Programme Innovation Connections Grant

Lead Product(s): Recce 327

Therapeutic Area: Infections and Infectious Diseases Product Name: Recce 327

Highest Development Status: Preclinical Product Type: Large molecule

Partner/Sponsor/Collaborator: Australian Government Department of Industry, Science, Energy and Resources

Deal Size: $0.02 million Upfront Cash: Undisclosed

Deal Type: Funding September 01, 2020

Details:

The grant will be directed towards project costs associated with assessing RECCE® 327 in the SARS-CoV-2 Antiviral Screening Program and is subject to performance based milestones.

Recce Pharmaceuticals

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

Australia

Post An Enquiry

Virtual Booth

ESMO 2020 Congress

Participation Not Confirmed

Update your events

Recce Pharmaceuticals Announces Positive Oral Data on New RECCE® 435 Against Helicobacter Pylori in Animal Model

Lead Product(s): RECCE 435

Therapeutic Area: Infections and Infectious Diseases Product Name: RECCE 435

Highest Development Status: Preclinical Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable August 05, 2020

Details:

New RECCE® 435 oral showed dose-dependent and efficacy against Helicobacter pylori (H. pylori) bacteria isolated from a patient with a duodenal ulcer compared to control vehicle in independent study model in rats.

Immuron

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

Australia

Post An Enquiry

Virtual Booth

ESMO 2020 Congress

Participation Not Confirmed

Update your events

Immuron Reports Neutralizing Activity Against SARS-CoV-2 Key Points

Lead Product(s): IMM-124E

Therapeutic Area: Infections and Infectious Diseases Product Name: IMM-124E

Highest Development Status: Preclinical Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable July 23, 2020

Details:

IMM-124E, the technology platform used to manufacture the company’s over-the-counter gastrointestinal & digestive health immune supplements Travelan® and Protectyn® has demonstrated neutralizing activity against SARS-CoV-2 in laboratory studies.

Avance Clinical

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

Australia

Post An Enquiry

Virtual Booth

ESMO 2020 Congress

Participation Not Confirmed

Update your events

Avance Clinical Contracted for Atossa Therapeutics AT-301 Nasal Spray Clinical Study

Lead Product(s): AT-301

Therapeutic Area: Infections and Infectious Diseases Product Name: AT-301

Highest Development Status: Preclinical Product Type: Undisclosed

Partner/Sponsor/Collaborator: Atossa Therapeutics

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Collaboration July 22, 2020

Details:

The study is a double-blinded, randomized, and placebo-controlled safety study of AT-301 nasal spray in 32 healthy adult subjects divided into two study groups.

Recce Pharmaceuticals

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

Australia

Post An Enquiry

Virtual Booth

ESMO 2020 Congress

Participation Not Confirmed

Update your events

Recce Pharmaceutical's RECCE® Compounds Selected by CSIRO/Doherty Institute in Priority 1 Candidate Group for SARS-CoV-2 Antiviral Screenin...

Lead Product(s): Recce 327

Therapeutic Area: Infections and Infectious Diseases Product Name: Recce 327

Highest Development Status: Preclinical Product Type: Large molecule

Partner/Sponsor/Collaborator: CSIRO

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Agreement July 08, 2020

Details:

RECCE® 327 and New RECCE® 529 compounds were selected for their unique mechanisms of action against hyper-mutation, as indicated on bacteria and viruses (respectively).

Zucero Therapeutics

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

Australia

Post An Enquiry

Virtual Booth

ESMO 2020 Congress

Participation Not Confirmed

Update your events

Zucero Therapeutics Announces Promising Covid-19 Virus Laboratory Results

Lead Product(s): Pixatimod

Therapeutic Area: Infections and Infectious Diseases Product Name: PG545

Highest Development Status: Preclinical Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable June 26, 2020

Details:

Zucero’s clinical-stage drug candidate pixatimod demonstrates potent antiviral activity against the COVID-19 virus in laboratory studies.

Vaxine

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

Australia

Post An Enquiry

Virtual Booth

ESMO 2020 Congress

Participation Not Confirmed

Update your events

Vaxine and Medytox partner on Covid-19 vaccine development

Lead Product(s): COVAX-19

Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

Highest Development Status: Preclinical Product Type: Vaccine

Partner/Sponsor/Collaborator: Medytox

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Collaboration May 25, 2020

Details:

The collaboration aims at developing a Covid-19 vaccine called, COVAX-19®, which is currently undergoing late stage animal testing and is based on Vaxine’s proprietary Advax™ adjuvant technology combined with a recombinant SARS-CoV-2 spike protein.

Cynata Therapeutics

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

Australia

Post An Enquiry

Virtual Booth

ESMO 2020 Congress

Participation Not Confirmed

Update your events

Cynata Receives Ethics Approval to Commence Clinical Trial in COVID-19 and Clinical Development Update

Lead Product(s): Cymerus mesenchymal stem cells

Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

Highest Development Status: Preclinical Product Type: Cell and Gene therapy

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable May 08, 2020

Details:

Ethics approval received for clinical trial in patients in intensive care with COVID-19 in Australia: the MEND (MEseNchymal coviD-19) Trial. The MEND trial is an open-label, randomised controlled clinical trial to investigate early efficacy of Cymerus MSCs.

Starpharma

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

Australia

Post An Enquiry

Virtual Booth

ESMO 2020 Congress

Participation Not Confirmed

Update your events

Starpharma to Develop COVID-19 Treatment

Lead Product(s): Astodrimer sodium

Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

Highest Development Status: Preclinical Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable April 16, 2020

Details:

Starpharma’s antiviral dendrimer, SPL7013, has been shown to have significant activity against SARS-CoV-21 (coronavirus), which causes COVID-19.

Noxopharm

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

Australia

Post An Enquiry

Virtual Booth

ESMO 2020 Congress

Participation Not Confirmed

Update your events

Noxopharm Investigating Potential COVID-19 Treatment

Lead Product(s): Idronoxil

Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

Highest Development Status: Preclinical Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable April 01, 2020

Details:

Noxopharm proposes to evaluate idronoxil use in patients at risk of developing acute respiratory distress syndrome (ARDS) and multi-organ failure associated with COVID-19 infection.

Find

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Product Type

Companies

Recce Pharmaceuticals

Recce Pharmaceuticals Receives Entrepreneurs’ Programme Innovation Connections Grant

Recce Pharmaceuticals

Recce Pharmaceuticals Announces Positive Oral Data on New RECCE® 435 Against Helicobacter Pylori in Animal Model

Immuron

Immuron Reports Neutralizing Activity Against SARS-CoV-2 Key Points

Avance Clinical

Avance Clinical Contracted for Atossa Therapeutics AT-301 Nasal Spray Clinical Study

Recce Pharmaceuticals

Recce Pharmaceutical's RECCE® Compounds Selected by CSIRO/Doherty Institute in Priority 1 Candidate Group for SARS-CoV-2 Antiviral Screenin...

Zucero Therapeutics

Zucero Therapeutics Announces Promising Covid-19 Virus Laboratory Results

Vaxine

Vaxine and Medytox partner on Covid-19 vaccine development

Cynata Therapeutics

Cynata Receives Ethics Approval to Commence Clinical Trial in COVID-19 and Clinical Development Update

Starpharma

Starpharma to Develop COVID-19 Treatment

Noxopharm

Noxopharm Investigating Potential COVID-19 Treatment